These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37863375)

  • 21. Identification of distinct cytokine/chemokine profiles in dermatomyositis with anti-transcriptional intermediary factor 1-γ antibody.
    Zhao Q; Chen Y; Diao L; Zhang S; Wu D; Xue F; Xia Q; Li H; Zheng J; Cao H
    Rheumatology (Oxford); 2022 May; 61(5):2176-2184. PubMed ID: 34508564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical features of juvenile dermatomyositis: A single-centre inception cohort.
    Cancarini P; Nozawa T; Whitney K; Bell-Peter A; Marcuz JA; Taddio A; Guo J; Dover S; Feldman BM
    Semin Arthritis Rheum; 2022 Dec; 57():152104. PubMed ID: 36183479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
    Suga T; Oiwa H; Ishida M; Iwamoto Y
    Clin Rheumatol; 2022 Sep; 41(9):2803-2808. PubMed ID: 35399148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China.
    Wen L; Chen X; Cheng Q; Nie L; Xu J; Yan T; Zhang X; Yang H; Sun W; Liu L; Xue J; Du Y
    Clin Rheumatol; 2022 Nov; 41(11):3419-3427. PubMed ID: 35859245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
    Fiorentino DF; Mecoli CA; Rosen MC; Chung LS; Christopher-Stine L; Rosen A; Casciola-Rosen L
    J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interstitial lung disease as an initial manifestation of dermatomyositis].
    Shen M; Gong Y; Zeng X; Zhang F; Tang F
    Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(43):3402-6. PubMed ID: 25622670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report.
    Kishi T; Tani Y; Okiyama N; Mizuochi K; Ichimura Y; Harigai M; Nagata S; Miyamae T
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):34. PubMed ID: 33740993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-PL-7, anti-Ro/SSA, anti-Mi-2, and anti-TIF1-γ correlate with specific patterns of histopathologic features in dermatomyositis: An analysis of 39 skin biopsy specimens from 25 patients.
    Bennett R; Bradley K; Stevanovic M; McFadden JR; Chaudhari AS; Ramos-Rodriguez AJ; Yan S; Momtahen S; LeBlanc RE; Cloutier JM; Salem I; Grand DG; Hodson EL; Sriharan A
    J Cutan Pathol; 2024 Apr; 51(4):317-326. PubMed ID: 38158735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dermatomyositis: Clinical features and pathogenesis.
    DeWane ME; Waldman R; Lu J
    J Am Acad Dermatol; 2020 Feb; 82(2):267-281. PubMed ID: 31279808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Case in Which Breast Cancer Developed at the Same Time As Dermatomyositis, and the Onset of New Cancer Was Able to Be Predicted by the Exacerbating Skin Symptoms and Parallel Increase in the Anti-TIF1-γ Antibody Levels.
    Akagi H; Wada T
    Intern Med; 2023; 62(20):3057-3062. PubMed ID: 37839875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review.
    Yeung TW; Cheong KN; Lau YL; Tse KN
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):103. PubMed ID: 34193210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
    Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
    Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
    Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
    J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Risk factors analysis and prediction model establishment of malignant tumor in patients with polymyositis/dermatomyositis].
    Wang YF; Li HX; Feng Y; Zhang Y; Wu ZB
    Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(25):1903-1910. PubMed ID: 37402671
    [No Abstract]   [Full Text] [Related]  

  • 35. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
    Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
    Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
    [No Abstract]   [Full Text] [Related]  

  • 36. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis.
    Oldroyd A; Sergeant JC; New P; McHugh NJ; Betteridge Z; Lamb JA; Ollier WE; Cooper RG; Chinoy H;
    Rheumatology (Oxford); 2019 Apr; 58(4):650-655. PubMed ID: 30535395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
    Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
    Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis.
    Selickaja S; Galindo-Feria AS; Dani L; Mimori T; Rönnelid J; Holmqvist M; Lundberg IE; Venalis P
    Rheumatology (Oxford); 2022 Nov; 61(12):4991-4996. PubMed ID: 35579337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features.
    Troyanov Y; Targoff IN; Payette MP; Raynauld JP; Chartier S; Goulet JR; Bourré-Tessier J; Rich E; Grodzicky T; Fritzler MJ; Joyal F; Koenig M; Senécal JL
    Medicine (Baltimore); 2014 Nov; 93(24):318-332. PubMed ID: 25500701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New-onset dermatomyositis following COVID-19: A case report.
    Shimizu H; Matsumoto H; Sasajima T; Suzuki T; Okubo Y; Fujita Y; Temmoku J; Yoshida S; Asano T; Ohira H; Ejiri Y; Migita K
    Front Immunol; 2022; 13():1002329. PubMed ID: 36353621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.